Cargando…

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories

Discrepancies exist for some of the modified coagulation factors when assayed with different one-stage clotting and chromogenic substrate assay reagents. The aim of this study was to evaluate the performance of a recombinant factor VIII Fc fusion protein (rFVIIIFc), currently in clinical development...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommer, J M, Moore, N, McGuffie-Valentine, B, Bardan, S, Buyue, Y, Kamphaus, G D, Konkle, B A, Pierce, G F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216409/ https://www.ncbi.nlm.nih.gov/pubmed/24261554 http://dx.doi.org/10.1111/hae.12296

Ejemplares similares

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity
por: Buyue, Yang, et al.
Publicado: (2014)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

The climate modelling primer /
por: McGuffie, K.
Publicado: (2014)

A climate modelling primer /
por: McGuffie, K.
Publicado: (1997)

A climate modelling primer
por: McGuffie, K.
Publicado: (2005)

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype
por: Driessler, Frank, et al.
Publicado: (2017)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories
por: Magnette, A., et al.
Publicado: (2016)

Real‐world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples
por: Sommer, Jurg M., et al.
Publicado: (2020)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

pLannotate: engineered plasmid annotation
por: McGuffie, Matthew J, et al.
Publicado: (2021)

Identifying widespread and recurrent variants of genetic parts to improve annotation of engineered DNA sequences
por: McGuffie, Matthew J., et al.
Publicado: (2023)

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
por: Georgescu, Maria T., et al.
Publicado: (2020)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
por: Malec, Lynn, et al.
Publicado: (2023)

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein
por: McCue, J, et al.
Publicado: (2014)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

The new oral anticoagulants and the future of haemostasis laboratory testing
por: Favaloro, Emmanuel J, et al.
Publicado: (2012)

Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII
por: Qu, Jingyao, et al.
Publicado: (2020)

Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa
por: Kannicht, Christoph, et al.
Publicado: (2020)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Haemobilia in a previously stented hilar cholangiocarcinoma: successful haemostasis after the insertion of fcSEMS
por: Tien, T, et al.
Publicado: (2020)

Inflammation and haemostasis
por: Margetic, Sandra
Publicado: (2012)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Thromboembolism and Haemostasis Programme
por: Hirsh, J., et al.
Publicado: (1972)

Haemostasis in Malignant Disease
por: Auger, M. J., et al.
Publicado: (1988)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
por: Bullement, Ash, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein In Vivo
por: Shi, Xunlong, et al.
Publicado: (2013)

Plant-produced recombinant Osteopontin-Fc fusion protein enhanced osteogenesis
por: Rattanapisit, Kaewta, et al.
Publicado: (2019)

A field study evaluating the activity of N8‐GP in spiked plasma samples at clinical haemostasis laboratories
por: Tiefenbacher, Stefan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u6579fgq0rqngpi2ugldk6aps4